Dergiler / Şişli Etfal Hastanesi Tıp Bülteni / 2019 / Cilt: 53 - Sayı: 3

The Association of Plasma Apelin Levels with Plaque Vulnerability

Sayfa
267–271
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Low plasma apelin levels may create a tendency towards vulnerable plaque and acute coronary syndrome.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: Apelin is a recently discovered peptide that is expressed in many tissues particularly in the cardiovascular system and exerts several actions, most of which are vasodilatory and positive inotropic effects.
📊
Temel Bulgular & Veri:Based on this, an apelin deficiency is believed to play a significant role in the development of hypertension and heart failure.
💡
Sonuç & Katkı:Conclusion: Low plasma apelin levels may create a tendency towards vulnerable plaque and acute coronary syndrome.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objectives: Apelin is a recently discovered peptide that is expressed in many tissues particularly in the cardiovascular system and exerts several actions, most of which are vasodilatory and positive inotropic effects. Based on this, an apelin deficiency is believed to play a significant role in the development of hypertension and heart failure. However, the association of apelin with the pathogenesis of atherosclerosis and especially plaque vulnerability remains unestablished. Thus, to contribute to the literature, in this study, we sought to determine the association of apelin concerning plaque vulnerability in the setting of the acute coronary syndrome. Methods: In this study, we prospectively enrolled a total of 80 patients; 40 with acute coronary syndrome and 40 patients with stable chronic ischemic heart disease. Plasma apelin levels were measured in all patients along with other routine biochemical parameters, and all patients underwent a transthoracic echocardiographic examination. Results: Plasma apelin levels were significantly lower in patients with the acute coronary syndrome (221.2±66.7 vs 254.3±77.9 p=0.04). However, there was no correlation between plasma apelin levels and serum inflammatory markers or coronary artery disease severity. Conclusion: Low plasma apelin levels may create a tendency towards vulnerable plaque and acute coronary syndrome.

🔖

Bu Makaleye Atıf Yap

KESKİN, K., YILDIZ, S. S., ÇETİNKAL, G., KİLCİ, H., ÇALIŞKAN, N., KESKİN, E. B., KILIÇKESMEZ, K. O. (2019). The Association of Plasma Apelin Levels with Plaque Vulnerability. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 53 - Sayı: 3, 267–271. https://ajindex.com/articles/363427

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998;251:471–6
  2. Salska A, Chiżyński K. Apelin - a potential target in the diagnosis and treatment of the diseases of civilization. Acta Cardiol 2016;71:505–17
  3. Smekal A, Vaclavik J. Adipokines and cardiovascular disease: A comprehensive review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2017 161:31–40
  4. Liakos CI, Sanidas EA, Perrea DN, Grassos CA, Chantziara V, Viniou NA, et al. Apelin and Visfatin Plasma Levels in Healthy Individuals With High Normal Blood Pressure. Am J Hypertens 2016:549–52
  5. Przewlocka-Kosmala M, Kotwica T, Mysiak A, Kosmala W. Reduced circulating apelin in essential hypertension and its association with cardiac dysfunction. J Hypertens 2011:971–9
  6. Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail 2006:355– 60
  7. Soeki T, Sata M. Inflammatory Biomarkers and Atherosclerosis. Int Heart J 2016;57:134–9
  8. Leeper NJ, Tedesco MM, Kojima Y, Schultz GM, Kundu RK, Ashley EA,et al. Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation. Am J Physiol Heart Circ Physiol 2009;296:H1329–35
  9. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L,et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015:233–70
  10. Siddiquee K, Hampton J, McAnally D, May L, Smith L. The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition. Br J Pharmacol 2013;16:1104–17
  11. Hashimoto T, Kihara M, Imai N, Yoshida S, Shimoyamada H, Yasuzaki H, et al. Requirement of apelin-apelin receptor system for oxidative stress-linked atherosclerosis. Am J Pathol 2007 171:1705–12
  12. Zhou Y, Wang Y, Qiao S. Apelin: a potential marker of coronary artery stenosis and atherosclerotic plaque stability in ACS patients. Int Heart J 2014;55:204–12
  13. Cosansu K, Cakmak HA, Ikitimur B, Yildirim E, Can G, Karadag B, et al. Apelin in ST segment elevation and non-ST segment elevation acute coronary syndromes: a novel finding. Kardiol Pol 2014;72:239–45
  14. Kuklinska AM, Sobkowicz B, Sawicki R, Mus